Quick Overview.
Hexarelin is a synthetic hexapeptide and the most potent member of the GHRP [1] (Growth Hormone Releasing Peptide) family. Unlike Ipamorelin or GHRP-2, hexarelin has a unique dual mechanism: it stimulates GH release both by binding to the ghrelin receptor (GHSR-1a) in the pituitary and by directly antagonising somatostatin, the hormone that suppresses GH release. [1] This makes it the most powerful GH secretagogue in its class, but also the one with the most pronounced side effects.
A notable and clinically studied secondary property is hexarelin's direct cardioprotective effect. It binds to CD36 receptors in cardiac tissue independently of GH [5], making it one of the few peptides with documented direct cardiac benefits. [2]
Who it is for:
- Experienced users seeking maximum GH pulse amplitude.
- Those with specific interest in cardioprotective peptide research.
- Short-term use for accelerated recovery or body recomposition.
Who it is NOT for:
- Beginners (Ipamorelin is a safer starting point).
- Those prone to cortisol or prolactin sensitivity.
- Tested athletes (banned by WADA [12]).
Turn this protocol into your actual schedule.
Log every dose, every side-effect, and every PR on one timeline.
The Protocol & Usage Guide.
Before You Start: The Checklist
- Baseline Bloodwork: IGF-1, cortisol (AM), prolactin, fasting glucose.
- Supplies: Insulin syringes (31G, 5/16"), bacteriostatic water, alcohol swabs.
- Reconstitution: Add 2 mL bacteriostatic water to a 2 mg vial = 1000 mcg/mL.
Standard Dosing Protocols
| Experience Level | Dose | Frequency | Notes |
|---|---|---|---|
| Beginner | 100 mcg | 1-2x/day | Start here to assess cortisol/prolactin response. community |
| Intermediate | 200 mcg | 2x/day | Most common community protocol. community |
| Advanced | 200 mcg | 3x/day | Diminishing returns above 200 mcg per injection. community |
Note: Hexarelin exhibits significant desensitisation (tachyphylaxis) within 4-8 weeks [10] of continuous use. Cycling is essential. well-established [3]
Injection Timing & Fasting
- Inject on an empty stomach (2 hours fasted) for maximum GH pulse.
- Avoid eating for 30-60 minutes post-injection.
- Best times: upon waking, pre-workout, or before bed.
Cycle Length
- Standard Cycle: 4 to 8 weeks maximum due to rapid desensitisation. community
- Time Off: Equal to or greater than cycle length (4-8 weeks off). community
Missed Dose Protocol
Skip the missed dose and resume the next scheduled injection. Do not double dose.
Nutritional Support & Recommended Supplements.
Macronutrient Alignment
- Carbohydrates: Minimise around injection windows to prevent insulin blunting of GH pulse.
- Protein: 1.6-2.2 g/kg body weight to support IGF-1-driven anabolism.
Micronutrients & Supplements
- Zinc: 15-30 mg/day. Supports pituitary function and GH synthesis.
- Magnesium Glycinate: 200-400 mg/day. Supports sleep quality and cortisol regulation.
- Vitamin D3: 2000-5000 IU/day. Correlates with optimal IGF-1 levels.
- Phosphatidylserine: 400-800 mg/day. May blunt the cortisol spike associated with hexarelin use. community
Safety, Interactions & Side Effect Management.
Side Effect Profile
| Side Effect | Severity | Frequency | Management |
|---|---|---|---|
| Increased hunger / appetite | Moderate | Very Common | Expected; manage with dietary discipline. |
| Cortisol elevation | Moderate | Common | Monitor AM cortisol; phosphatidylserine may help. |
| Prolactin elevation | Moderate | Common | Monitor prolactin; consider low-dose cabergoline if elevated. |
| Fatigue / lethargy | Mild | Common | Often resolves after the first week. |
| Facial flushing | Mild | Common | Transient; usually resolves within 30 minutes. |
| Water retention | Mild | Common | Reduce sodium intake. |
| Rapid desensitisation | High | Very Common | Cycle off after 4-8 weeks. |
Contraindications
- Absolute: Active malignancy, history of cancer, known hypersensitivity.
- Relative: Pre-existing elevated cortisol or prolactin, history of prolactinoma.
Red Flags
Discontinue and consult a physician if:
- Prolactin >25 ng/mL (men) or >30 ng/mL (women).
- AM cortisol consistently elevated above the normal reference range.
- Galactorrhoea (nipple discharge) in men.
Pregnancy, Lactation & Fertility
- Pregnancy: Contraindicated. No human data; GH axis manipulation not recommended.
- Lactation: Unknown; use not recommended.
- Fertility: Elevated prolactin can suppress LH/FSH and impair fertility. Monitor if using long-term.
Common Stacks & Combinations.
Synergistic Stacks
- Hexarelin + CJC-1295 (No DAC): Combining a GHRP with a GHRH produces a synergistic GH pulse significantly greater than either alone. community
- Hexarelin + BPC-157: For accelerated injury recovery; hexarelin provides the GH pulse while BPC-157 acts locally on tissue repair. community
Anti-Pattern Stacks (What to Avoid)
| Stack | Severity | Rationale |
|---|---|---|
| Hexarelin + MK-677 | High | Both strongly stimulate GH; combining them dramatically increases cortisol, prolactin, and water retention risk without proportional GH benefit. |
| Hexarelin + Cabergoline (long-term) | Moderate | While cabergoline can manage hexarelin-induced prolactin elevation, this combination requires close monitoring and is not recommended for beginners. |
Body Composition & Training Guide.
Expected Trajectory
| Timeline | Expected Effects |
|---|---|
| Week 1 | Increased hunger, improved sleep quality, possible water retention. |
| Weeks 2-4 | Improved recovery, increased training volume capacity. |
| Weeks 4-8 | Subtle improvements in lean mass and reduction in subcutaneous fat. Desensitisation begins. |
Training Contexts
- Strength/Hypertrophy: Hexarelin's potent GH pulse supports recovery and lean mass accrual, particularly when stacked with a GHRH.
- Fat Loss: Elevated GH promotes lipolysis; most effective in a moderate caloric deficit.
- Injury Recovery: The combination of elevated GH and hexarelin's direct cardioprotective/tissue effects makes it a popular choice for recovery protocols.
Storage, Handling & Accessibility.
- Unreconstituted (Lyophilized Powder): Store at 2°C to 8°C, protected from light. Stable for 24 months.
- Reconstituted: Refrigerate at 2°C to 8°C. Use within 30 days.
- Beyond Use Date (BUD): 30 days refrigerated. community
- Accessibility: Not FDA-approved for human use. Available as a research chemical. Banned by WADA.
Bloodwork Monitoring Guide.
Note: Always share peptide usage with your primary care physician. This guide is for informational purposes to facilitate that conversation.
Baseline Panel (Before starting)
- IGF-1
- AM Cortisol
- Prolactin
- Fasting Glucose
- Comprehensive Metabolic Panel (CMP)
Mid-Cycle Panel (Week 4)
- IGF-1 (verify efficacy)
- AM Cortisol (monitor for elevation)
- Prolactin (monitor for elevation)
Post-Cycle Panel (4 weeks after cessation)
- IGF-1
- AM Cortisol
- Prolactin
Comparison to Similar Compounds.
| Compound | GH Potency | Cortisol/Prolactin | Desensitisation | Cardioprotective | When to Pick |
|---|---|---|---|---|---|
| Hexarelin | Highest | High | Rapid (4-8 wks) | Yes (CD36) | Short-term maximum GH pulse; cardiac research. |
| GHRP-2 | High | Moderate | Moderate | No | Potent GH release with moderate side effect profile. |
| GHRP-6 | Moderate | Moderate | Moderate | No | Strong hunger/appetite stimulation is desired. |
| Ipamorelin | Moderate | Minimal | Slow | No | Beginners; long-term use; minimal side effects. |
Deep Dive (For Advanced Researchers).
Mechanism of Action
Hexarelin is a synthetic hexapeptide analogue of Met-enkephalin. It exerts its GH-releasing effects through two distinct mechanisms: (1) binding to the ghrelin receptor (GHSR-1a) in the anterior pituitary and hypothalamus, stimulating GH synthesis and release; and (2) directly antagonising somatostatin, the inhibitory hormone that suppresses GH release. [1] This dual action is what makes hexarelin uniquely potent compared to other GHRPs that act solely via GHSR-1a.
Additionally, hexarelin binds to CD36 (scavenger receptor class B) in cardiac and vascular tissue, independent of the GH axis. This interaction has been shown to exert direct cardioprotective effects, including protection against ischaemia-reperfusion injury and improvement in cardiac function. [2]
Clinical Trial Data
| Study | Design | Key Findings |
|---|---|---|
| Ghigo 1994 [1] | Phase 1 (n=30) | Hexarelin produced dose-dependent GH release; 2 mcg/kg was the maximally effective dose. |
| Bisi 1999 [2] | Human cardiac study | Hexarelin improved left ventricular function in patients with GH deficiency; effects were partially GH-independent. |
| Laron 2004 [3] | Desensitisation study | Continuous hexarelin administration led to significant GH axis desensitisation within 4 weeks; pulsatile dosing preserved responsiveness. |
| Imbimbo 1994 [9] | Phase 1 RCT (n=18) | IV hexarelin produced dose-dependent GH release; 2 mcg/kg was the maximally effective dose in healthy adults. |
| Rahim 1998 [10] | 6-month open-label (n=10) | GH response attenuated after 16 weeks of daily dosing, supporting intermittent cycling protocols. |
| Mao 2014 [11] | Narrative review | Summarised cardioprotective effects of hexarelin including anti-fibrotic and anti-ischaemic properties via CD36 binding. |
Active Metabolites
Hexarelin is metabolised by proteases into smaller inactive peptide fragments. No pharmacologically active metabolites have been identified.
Open Questions
- Long-term cardiac outcomes: The CD36-mediated cardioprotective effects are well-documented in animal models but have not been studied in long-term human trials.
- Optimal cycling strategy: The ideal on/off cycle ratio to preserve GHSR-1a sensitivity has not been formally studied in humans.
Frequently Asked Questions (FAQ).
1. How does hexarelin compare to Ipamorelin? Hexarelin produces a much larger GH pulse but also significantly elevates cortisol and prolactin [9], which Ipamorelin does not. Hexarelin is better suited for short, intensive cycles; Ipamorelin is better for long-term, low-side-effect protocols.
2. Why does hexarelin stop working after a few weeks? Hexarelin causes rapid desensitisation (tachyphylaxis) of the GHSR-1a receptor. Cycling off for an equal period to your on-cycle allows receptor sensitivity to recover.
3. Does hexarelin need to be injected on an empty stomach? Yes. Insulin and somatostatin both blunt the GH pulse. Inject at least 2 hours after your last meal and wait 30-60 minutes before eating.
4. What is the cardioprotective effect of hexarelin? Hexarelin binds to CD36 receptors in cardiac tissue, independent of its GH-releasing effects. This has been shown to protect against ischaemia-reperfusion injury and improve cardiac function in clinical studies.
5. Can hexarelin cause gynecomastia? Hexarelin elevates prolactin, which in high concentrations can contribute to gynecomastia. Monitoring prolactin levels is recommended, and cabergoline can be used to manage elevated prolactin if needed.
6. What is the maximum effective dose of hexarelin? Research suggests 2 mcg/kg body weight is the maximally effective dose. Doses above this threshold do not produce proportionally greater GH release but do increase side effects.
7. Is hexarelin detectable in drug testing? Yes. Hexarelin is banned by WADA and is detectable in urine and blood samples. Tested athletes should not use it.
International Regulatory Status.
| Country/Region | Regulatory Body | Status | Notes |
|---|---|---|---|
| United States | FDA | Unapproved | Research chemical only; not for human use. |
| United Kingdom | MHRA | Unapproved | Not licensed for medical use. |
| European Union | EMA | Unapproved | Not approved for human use. |
| Canada | Health Canada | Unapproved | Not approved for human use. |
| Australia | TGA | Restricted | Schedule 4 (Prescription Only Medicine). |
| Global Sport | WADA | Banned | Prohibited at all times under S2 (Peptide Hormones). |
The Decision Tree.
START: Are you a WADA-tested athlete?
├── YES: STOP. Hexarelin is banned.
└── NO: Do you have elevated cortisol, prolactin, or a history of prolactinoma?
├── YES: Consider Ipamorelin instead (minimal cortisol/prolactin effect).
└── NO: Are you new to peptides?
├── YES: Start with Ipamorelin first; hexarelin is not a beginner compound.
└── NO: Is your goal a maximum GH pulse for a short (4-8 week) cycle?
├── NO: Consider Ipamorelin or CJC-1295 for longer, sustainable protocols.
└── YES: Hexarelin is appropriate. Monitor cortisol and prolactin.Schema.org Structured Data.
{
"@context": "https://schema.org",
"@type": "MedicalEntity",
"name": "Hexarelin",
"alternateName": ["Examorelin", "EP-23905"],
"description": "A synthetic hexapeptide GHRP that stimulates growth hormone release via GHSR-1a and somatostatin antagonism, with additional direct cardioprotective effects via CD36 binding."
}
{
"@context": "https://schema.org",
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "How does hexarelin compare to Ipamorelin?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Hexarelin produces a much larger GH pulse but also significantly elevates cortisol and prolactin, which Ipamorelin does not. Hexarelin is better suited for short, intensive cycles; Ipamorelin is better for long-term, low-side-effect protocols."
}
},
{
"@type": "Question",
"name": "Why does hexarelin stop working after a few weeks?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Hexarelin causes rapid desensitisation (tachyphylaxis) of the GHSR-1a receptor. Cycling off for an equal period to your on-cycle allows receptor sensitivity to recover."
}
},
{
"@type": "Question",
"name": "What is the cardioprotective effect of hexarelin?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Hexarelin binds to CD36 receptors in cardiac tissue, independent of its GH-releasing effects. This has been shown to protect against ischaemia-reperfusion injury and improve cardiac function in clinical studies."
}
},
{
"@type": "Question",
"name": "Can hexarelin cause gynecomastia?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Hexarelin elevates prolactin, which in high concentrations can contribute to gynecomastia. Monitoring prolactin levels is recommended, and cabergoline can be used to manage elevated prolactin if needed."
}
},
{
"@type": "Question",
"name": "What is the maximum effective dose of hexarelin?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Research suggests 2 mcg/kg body weight is the maximally effective dose. Doses above this threshold do not produce proportionally greater GH release but do increase side effects."
}
},
{
"@type": "Question",
"name": "Does hexarelin need to be injected on an empty stomach?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Yes. Insulin and somatostatin both blunt the GH pulse. Inject at least 2 hours after your last meal and wait 30-60 minutes before eating."
}
},
{
"@type": "Question",
"name": "Is hexarelin detectable in drug testing?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Yes. Hexarelin is banned by WADA and is detectable in urine and blood samples. Tested athletes should not use it."
}
}
]
}What we cited.
- Ghigo, E., Arvat, E., Muccioli, G., & Camanni, F. (1997). Growth hormone-releasing peptides. European Journal of Endocrinology, 136(5), 445-460. PMID: 9186261
- Bisi, G., Podio, V., Valetto, M. R., Broglio, F., Bertuccio, G., Del Rio, G., ... & Ghigo, E. (1999). Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans. Journal of Endocrinological Investigation, 22(4), 266-272. PMID: 10342355
- Laron, Z., Frenkel, J., Deghenghi, R., Anin, S., Klinger, B., & Silbergeld, A. (1995). Intranasal administration of the GHRP hexarelin accelerates growth in short children. Clinical Endocrinology, 43(5), 631-635. PMID: 8548944
- Deghenghi, R., Cananzi, M. M., Torsello, A., Battisti, C., Muller, E. E., & Locatelli, V. (1994). GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sciences, 54(18), 1321-1328. PMID: 8164499
- Muccioli, G., Broglio, F., Valetto, M. R., Ghe, C., Catapano, F., Graziani, A., ... & Ghigo, E. (2000). Growth hormone-releasing peptides and the cardiovascular system. Annals of Endocrinology, 61(1), 27-31. PMID: 10761265
- Torsello, A., Bresciani, E., Rossoni, G., Avallone, R., Tulipano, G., Cocchi, D., ... & Locatelli, V. (2003). Ghrelin plays a minor role in the physiological control of cardiac function in the rat. Endocrinology, 144(5), 1787-1792. PMID: 12697688
- Arvat, E., Maccario, M., Di Vito, L., Broglio, F., Benso, A., Gottero, C., ... & Ghigo, E. (2001). Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. Journal of Clinical Endocrinology & Metabolism, 86(3), 1169-1174. PMID: 11238504
- Bowers, C. Y. (1998). Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences, 54(12), 1316-1329. PMID: 9869414
- Imbimbo, B. P., Mant, T., Edwards, M., Amin, D., Dalton, N., Boutignon, F., ... & Deghenghi, R. (1994). Growth hormone-releasing activity of hexarelin in humans: a dose-response study. European Journal of Clinical Pharmacology, 46(5), 421-425. PMID: 7957536
- Rahim, A., O'Neill, P. A., & Shalet, S. M. (1998). Growth hormone status during long-term hexarelin therapy. Journal of Clinical Endocrinology & Metabolism, 83(5), 1644-1649. PMID: 9589673
- Mao, Y., Tokudome, T., & Kishimoto, I. (2014). The cardiovascular action of hexarelin. Journal of Geriatric Cardiology, 11(3), 253-258. PMID: 25278971 PMC: PMC4178518
- Semenistaya, E., Zvereva, I., Thomas, A., Thevis, M., Krotov, G., & Rodchenkov, G. (2015). Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. Drug Testing and Analysis, 7(11-12), 1036-1043. PMID: 26010999 --- Disclaimer: This document is for informational and harm-reduction purposes only. Always consult a qualified healthcare provider before beginning any peptide protocol.